Suven Pharmaceuticals Ltd - SUVEN PHARMA Share Price

Sector: Pharmaceuticals | ISIN: INE03QK01018
₹ 561.35 (3.18%) icon29 Sep, 2023, 3:59:52 PM

Suven Pharmaceuticals Ltd Stock View

info icon
Edit Image
Target | 11 Aug, 2023 580.667 (3.44%)

Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Phar... Read More

Suven Pharmaceuticals Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:59:52 PM

    ₹ 561.35 17.30 3.18
  • Open
  • ₹ 547
  • Prev. Close
  • ₹ 544.05
  • Turnover(Lac.)
  • ₹ 2,480
  • Day's High
  • ₹ 567
  • Day's Low
  • ₹ 544.1
  • 52 Week's High
  • ₹ 567
  • 52 Week's Low
  • ₹ 390.5
  • Book Value
  • ₹ 81.61
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 14,290
  • P/E
  • 32.26
  • EPS
  • 17.4
  • Divi. Yield
  • 1.07

Suven Pharmaceuticals Ltd Corporate Actions

01 Aug , 2023

12:00 AM

01 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2023

12:00 AM

01 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Nov , 2022

12:00 AM


Suven Pharmaceuticals Ltd News and Update

Image not found
  • 29 September, 2023 |
  • 8:36 PM

According to a BSE notification dated September 28, it will be involved in the importing, warehousing, distribution, and exportation of pharmaceuticals.

Image not found
Image not found
  • IIFL News Service |
  • 26 September, 2023 |
  • 8:31 PM
Image not found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Suven Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT
02 October , 2023 | 10:24 PM

PROMOTER - TOTAL60.00%

Indian: 60.00%

Foreign: 0%

NON-PROMOTER - TOTAL 40.00%

Institutions: 20.13%

Non-Institutions: 19.87%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Suven Pharmaceuticals Ltd FINANCIALS

Suven Pharmaceuticals Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Suven Pharmaceuticals Ltd

  • Venkateswarlu Jasti
  • Managing Director
  • Deepanwita Chattopadhyay
  • Independent Director
  • V Sambasiva Rao
  • Independent Director
  • Jerry Jeyasingh
  • Non-Exec & Non-Independent Dir
  • Hanumantha Rao Kokkonda
  • Company Secretary
  • D G Prasad
  • Independent Director
  • J V Ramudu
  • Chairman & Non Executive Dir.

Summary

Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged... Read More


Reports by Suven Pharmaceuticals Ltd


Reports by Suven Pharmaceuticals Ltd

Company FAQ

No Record Found